Experimental drug tested for Tough-to-Treat cancers
NCT ID NCT04504916
Summary
This study tested an experimental drug called VLS-101 (zilovertamab vedotin) in 102 people with advanced solid tumors that had spread and stopped responding to previous treatments. The trial aimed to see if the drug could shrink tumors and was safe for cancers including breast, lung, ovarian, gastric, and pancreatic cancers. The study was terminated early, and results were collected to understand how the drug performed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Orlando ( Site 0003)
Orlando, Florida, 32804, United States
-
BC Cancer Vancouver ( Site 0011)
Vancouver, British Columbia, V5Z 4E6, Canada
-
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
Québec, Quebec, G1J 1Z4, Canada
-
Centre intégré de cancérologie du CHUM ( Site 0016)
Montreal, Quebec, H2X 0A9, Canada
-
Cross Cancer Institute ( Site 0012)
Edmonton, Alberta, T6G 1Z2, Canada
-
Jewish General Hospital ( Site 0013)
Montreal, Quebec, H3T 1E2, Canada
-
John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0002)
Hackensack, New Jersey, 07601, United States
-
MD Anderson ( Site 0001)
Houston, Texas, 77030, United States
-
Massachusetts General Hospital ( Site 0017)
Boston, Massachusetts, 02114, United States
-
Memorial Regional Hospital-Memorial Cancer Institute ( Site 0005)
Hollywood, Florida, 33021, United States
-
Memorial Sloan Kettering Cancer Center ( Site 0007)
New York, New York, 10021, United States
-
Princess Margaret Cancer Centre ( Site 0006)
Toronto, Ontario, M5G 2M9, Canada
-
Swedish Medical Center ( Site 0008)
Seattle, Washington, 98104, United States
-
The University of Texas Health Science Center at San Antonio ( Site 0004)
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.